Huynh et al. recently reported that treatment of human HCC xenografts with AZD6244 (ARRY-142886, Selumetinib), a selective MEK inhibitor, blocked ERK1/2 activation, reduced in vivo tumor growth and induced apoptosis [44]. The gene discussed is MAP2K7; the disease is neoplasm.